Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Theiler's virus infection of the central nervous system (CNS) induces an immune‐mediated demyelinating disease in susceptible mouse strains and serves as a relevant infection model for human multiple sclerosis (MS). Cannabinoids have been shown to exert beneficial effects on animal models of MS and evidence suggests that the endocannabinoid system plays a role in the tonic control of spasticity. In this study we show that OMDM1 [(R)‐N‐oleoyl‐(1′‐hydroxybenzyl)‐2′‐ethanolamine] and OMDM2 [(S)‐N‐oleoyl‐(1′‐hydroxybenzyl)‐2′‐ethanolamine], two selective inhibitors of the putative endocannabinoid transporter and hence of endocannabinoid inactivation, provide an effective therapy for Theiler murine encephalomyelitis virus‐induced demyelinating disease (TMEV‐IDD). Treatment of TMEV‐infected mice with OMDM1 and OMDM2 enhanced anandamide levels in the spinal cord and ameliorated motor symptoms. This was associated with a down‐regulation of inflammatory responses in the spinal cord. In addition we show that OMDM1 and OMDM2 down‐regulate macrophage function by (i) decreasing the surface expression of major histocompatibility complex (MHC) class II molecules, (ii) inhibiting nitric oxide synthase‐2 (NOS‐2) expression and (iii) reducing the production of the pro‐inflammatory cytokines interleukin‐1beta (IL‐1β) and interleukin‐12 (IL‐12p40). Taken together, these results point to the manipulation of the endocannabinoid system as a possible strategy to develop future MS therapeutic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 2×
“…endogenous ligands of cannabinoid receptors, the endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) (Devane et al. 1992; Mechoulam et al. 1995), and a degradation system including a re-uptake mechanism and hydrolytic enzymes for these compounds, have been identified (Di…”
BackgroundInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208 · cited 2×
“…AEA and 2- AG, were obtained and pre-purified by means of open bed silica chromatography as previously described (Fontana et al. 1995), whereas the endogenous levels of the two endocannabinoids were measured by isotope dilution as described previously (Di Marzo et al. 2000; Marsicano et al. 2003).”
MethodZajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Olson, J. K., Girvin, A. M., & Miller, S. D. (2001) · Journal of Virology · doi:10.1128/jvi.75.20.9780-9789.2001 · Cited by 178
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…with the transport inhibitors OMDM1 and OMDM2 enhanced anandamide levels, down-regulated inflammatory responses in the spinal cord, and ameliorated motor symptoms (Mestre et al., 2005), and similar findings PACHER et al. Page 25 Pharmacol Rev. Author manuscript; available in PMC 2008 February 13.”
BackgroundTargeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Self-citationCannabinoids as Novel Anti-Inflammatory Drugs
Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.93 · Cited by 555
“IL-12 and IFN-γ have been shown to reduce FAAH activity and protein expression of FAAH, whereas IL-4 or IL-10 stimulated FAAH activity [39].”
InfluentialModulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli
Maresz, K., Carrier, E. J., Ponomarev, E. D., Hillard, C. J., & Dittel, B. N. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03380.x · Cited by 482
Endocannabinoids: synthesis and degradation
Di Marzo, V. (2006) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/112_0505 · Cited by 311
Self-citation
Metadata
- Authors
- Mestre, L., Correa, F., Arévalo‐Martín, A., Molina‐Holgado, E., Valenti, M., Ortar, G., Di Marzo, V., & Guaza, C.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2005-02-17
- Volume
- 92
- Issue
- 6
- Pages
- 1327-1339
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1556923935
- Cited by
- 134
- References
- 9
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. https://app.cochat.ai/papers/10.1111/j.1471-4159.2004.02979.x
- The paper
- Mestre, L., Correa, F., Arévalo‐Martín, A., Molina‐Holgado, E., Valenti, M., Ortar, G., Di Marzo, V., & Guaza, C. (2005). Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2004.02979.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.